Breakeven Date Change • May 21
Forecast to breakeven in 2028 The 3 analysts covering Isofol Medical expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 14% per year to 2027. The company is expected to make a profit of kr56.8m in 2028. Average annual earnings growth of 63% is required to achieve expected profit on schedule. New Risk • May 20
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr54m Forecast net loss in 2 years: kr16m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (98% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr16m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (kr229.8m market cap, or US$24.6m). Breakeven Date Change • May 19
Forecast to breakeven in 2028 The 3 analysts covering Isofol Medical expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr56.8m in 2028. Average annual earnings growth of 54% is required to achieve expected profit on schedule. Announcement • Mar 09
Isofol Medical AB (publ), Annual General Meeting, May 19, 2026 Isofol Medical AB (publ), Annual General Meeting, May 19, 2026. New Risk • Feb 24
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 4.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 4.4% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (74% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr59m net loss in 2 years). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (kr227.1m market cap, or US$25.1m). Announcement • Nov 24
Isofol Medical AB (publ) to Report Q3, 2026 Results on Nov 12, 2026 Isofol Medical AB (publ) announced that they will report Q3, 2026 results on Nov 12, 2026 New Risk • Nov 15
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.6% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 3.6% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (74% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr61m net loss in 2 years). Market cap is less than US$100m (kr195.4m market cap, or US$20.7m). Announcement • Aug 26
Isofol Medical AB (publ) to Report Q1, 2026 Results on May 19, 2026 Isofol Medical AB (publ) announced that they will report Q1, 2026 results on May 19, 2026 New Risk • Jul 31
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 74% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (74% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr32m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (kr254.8m market cap, or US$26.0m). Announcement • Jul 11
Isofol Medical AB (publ) announced that it expects to receive SEK 4.999997 million in funding Isofol Medical AB (publ) announced a private placement of 6,249,996 shares at a price SEK 0.8 per share for gross proceeds SEK 4,999,996.80 on July 9, 2025. The transaction includes participation from Solasia Pharma K.K. The transaction is expected to close on Mid of July. Announcement • Jun 03
Isofol Medical AB (publ) Announces Pre-IND Meeting with the FDA for Arfolitixorin Isofol Medical AB (publ) announced that the company has been granted a Pre-IND meeting with the U.S. Food and Drug Administration (FDA) ahead of a planned Investigational New Drug (IND) application. An IND application aims to pave the way for clinical studies with arfolitixorin in the US. Isofol is developing arfolitixorin to enhance the effectiveness of standard treatments given to patients with severe forms of cancer. The company is currently conducting a phase Ib/II clinical study in Germany in patients with metastatic colorectal cancer, aiming at evaluating the safety and tolerability of arfolitixorin at ascending doses, while also capturing indicationss of efficacy. In the second part of the study, where efficacy parameters will be the primary endpoints, an expansion of the study to additional countries is being planned. The U.S. Food and drug Administration (FDA), which is responsible for the approval of new treatments, has now granted Isofol's request for a Pre-IND meeting ahead of a planned submission of an Investigational New Drug (IND). The dialogue with the FDA and the IND process aim to enable clinical development in the US. Announcement • Feb 19
Isofol Medical AB (publ) to Report Fiscal Year 2025 Results on Feb 18, 2026 Isofol Medical AB (publ) announced that they will report fiscal year 2025 results on Feb 18, 2026 New Risk • Feb 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (kr323.0m market cap, or US$30.2m). Announcement • Sep 17
Isofol Medical AB (Publ) Strengthens the Outlook for Further Extending the Patent Protection of Its Drug Candidate Arfolitixorin Isofol Medical AB (publ), announced positive outcomes of a preliminary patentability report on a new international product patent application for arfolitixorin, submitted under the PCT (Patent Cooperation Treaty). If granted, the patent could significantly strengthen and prolong arfolitixorin’s intellectual property protection internationally. The intellectual property protecting Isofol’s drug candidate arfolitixorin, which is in development for metastatic colorectal cancer, consists of a combination of product (composition-of-matter/formulation) and clinical use/dose patents that provides for strong protection and market exclusivity across key markets globally. As Isofol is continuing the clinical development of arfolitixorin, the company and its partners are continuously working towards further extending the scope and duration of the intellectual property protection. Isofol announces that a positive preliminary patentability report from the international searching authority of the European Patent Office (EPO) on a new international product patent application relating to stable dosage forms of arfolitixorin has been issued. The application, which has been filed under the Patent Cooperation Treaty, covers pharmaceutical compositions comprising arfolitixorin in the form of stable lyophilizates for use in clinical settings. Obtaining a positive patentability report from a recognized international searching authority is an important step in the patent process and means that a new product patent covering arfolitixorin is likely (but not guaranteed) to be granted over the next 2-3 years, subject to decisions made by national/regional patent offices. The ensuing patents will have an expected expiry in the mid- 2040s, and span across Isofol’s key markets, including but not limited to the United States, Europe and Japan. Given its scope, potential geographic coverage and long duration, this patent is deemed to be of high importance for Isofol and its partners. Announcement • Jul 17
Isofol Medical AB (Publ) Announces New Preclinical Data Supporting the Previously Communicated Clinical Development Plan for Arfolitixorin Isofol Medical AB (publ) announced results from two preclinical studies that support the dose-response relationship for arfolitixorin. These positive data further strengthen the hypothesis behind the design of the clinical Phase Ib/II study in patients with colorectal cancer that Isofol plans to conduct in collaboration with one of Europe's leading university hospitals, Charité – Universitätsmedizin Berlin. The preclinical studies were conducted by Oncosyne AS in collaboration with Akershus University Hospital in Oslo, and at the Surgical Oncology Laboratory (SOL) at Sahlgrenska University Hospital in Gothenburg, respectively. Both studies show that increased doses of arfolitixorin in combination with 5-FU lead to significantly higher efficacy. The studies also investigated the addition of PLP (the active form of vitamin B6) and with the analysis methods applied, neither found any additive efficacy in combination with arfolitixorin. The results from the study conducted at SOL further show that increased doses of the comparator product leucovorin in combination with 5-FU do not lead to higher efficacy, in contrast to arfolitixorin’s clear dose-response relationship. This indicates that the differences between arfolitixorin and leucovorin may be further amplified at a higher dose level. These preclinical studies confirm previous findings and thereby provide further support for Isofol’s strategy to conduct a clinical study with an optimized dosing regimen of arfolitixorin, where higher doses than the one used in the Phase III AGENT study are tested. The Phase Ib/II study with arfolitixorin will be conducted in collaboration with Charité – Universitätsmedizin Berlin and the Clinic for Hematology, Oncology, and Tumor Immunology (CCM) under the leadership of Prof. Dr. med. Sebastian Stintzing. Announcement • Jun 13
Isofol Medical AB (Publ) Announces That Magnus Hurst, Chief Financial Officer to Leave the Company, Effective from September 2, 2024 Isofol Medical AB (publ) announced that Magnus Hurst, Chief Financial Officer, is leaving the company at the beginning of September for family reasons. Magnus Hurst has held the position as CFO on a part-time consultancy basis since January this year. During the autumn, Magnus will be going on parental leave and will therefore leave his consulting assignment in the company. Isofol is now starting a recruitment process to appoint a successor. Magnus will continue in his role as CFO until September 2, 2024. New Risk • Mar 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (kr721k revenue, or US$69k). Minor Risk Market cap is less than US$100m (kr145.4m market cap, or US$13.9m). Reported Earnings • Feb 22
Full year 2023 earnings released: kr0.23 loss per share (vs kr0.99 loss in FY 2022) Full year 2023 results: kr0.23 loss per share (improved from kr0.99 loss in FY 2022). Net loss: kr37.1m (loss narrowed 77% from FY 2022). Announcement • Feb 08
Isofol Medical AB (publ), Annual General Meeting, May 08, 2024 Isofol Medical AB (publ), Annual General Meeting, May 08, 2024. Announcement • Jan 12
Isofol Medical AB (publ) Announces Chief Financial Officer Changes Isofol Medical AB (publ) announced that the company has appointed Magnus Hurst as new Chief Financial Officer. He has broad financial experience and takes up the position with immediate effect. Magnus Hurst has long experience in financial roles at companies such as SAS and within the Kinnevik Group. He currently holds a position as CFO and Head of Investor Relations at the biotech company Synartro and will combine this role with the new assignment as CFO at Isofol. Magnus holds an M.Sc. in Finance from Bayes Business School, UK, as well as a B.Sc. in Business Studies and an LL.M from Uppsala University, Sweden. Magnus Hurst succeeds Roy Jonebrant, who has been acting CFO on a consultacy basis since March 2023 and whose contract expires at the end of January 2024. Announcement • Jan 09
Isofol Medical AB (publ) Announces CEO Changes Isofol Medical AB (publ) announced that its Board of Directors has appointed Petter Segelman Lindqvist as new Chief Executive Officer. He has extensive experience from leading roles in several international pharmaceutical companies and takes up the position with immediate effect. Petter Segelman Lindqvist has a MSc in Business and Economics from the Stockholm School of Economics, Sweden, and EM Lyon, France. He has experiences from leading positions in the pharmaceutical industry, including within GlaxoSmithKline, AbbVie and Sobi (Swedish Orphan Biovitrum), as well as from board work in smaller biotech companies. He contributes with knowledge of strategic business development and partnerships, global commercialization, and product development. He has led several product launches and has taken drug candidates through clinical development and regulatory processes to market introduction. Petter Segelman Lindqvist succeeds Roger Tell who has been acting CEO since June 2023. Announcement • Dec 29
Isofol Medical AB (Publ) Presents Additional Results from Laboratory Tests with Arfolitixorin Showing Supplementary Effects Isofol Medical AB (publ) announced that the company has received additional results from the laboratory tests conducted with arfolitixorin ahead of a potential decision on the drug candidate's continued clinical development. The results show interesting supplementary effects of arfolitixorin in two of a total of five evaluated organoids from colorectal cancer tumors. These findings are positive for Isofol and the company will implement additional bioinformatic analysis to identify potential patterns. Isofol has received further results from the laboratory tests carried out as part of the company's stepwise process to enable a cost-effective evaluation of the drug candidate arfolitixorin. The results originate from tests on organoids from tumors in the colon and rectum and show additional effects of arfolitix orin in two of a totalof five organoids studied, an effect that was not seen with leucovorin. The additional effect was shown as an enhancement of the response to the chemotherapy drug 5-FU, both in terms of reducing tumor size and the ability to induce cell death. In three out of five organoid tests, however, no additional effect of any of the folates in combination with 5-FU was seen. Data from the laboratory tests will undergo bioinformatics analyses to identify molecular patterns associated with folate sensitivity. These analyses may provide further support in the construction of a hypothesis for the continued development of arfolitixor in. Announcement • Dec 13
Isofol Medical AB (Publ) Appoints Jan-Eric Österlund as Member of the Board Isofol Medical AB (publ) announced that all of the company's board members will leave their respective positions if Jan-Eric Österlund is elected as a new member of the board at the extraordinary general meeting that has been convened on a request from a group of minority shareholders. Following a request from a group of shareholders representing more than 10% of the company shares (the "Minority Shareholders"), an extraordinary general meeting will be held on January 4, 2024. The minority shareholders propose the election of four new members of the board, including Jan-Eric Österlund. All current members of the board announce their decision to resign from their respective posts if Jan-Eric Österlund is elected as a new member of the board at the extraordinary general meeting. New Risk • Dec 08
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr95.0m (US$9.05m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 3.4% per year over the past 5 years. Revenue is less than US$1m (kr2.6m revenue, or US$246k). Market cap is less than US$10m (kr95.0m market cap, or US$9.05m). Announcement • Dec 08
Isofol Receives the First Results from Laboratory Tests of Arfolitixorin Isofol Medical AB (publ) announced that the company has received the first results from the laboratory tests of arfolitixorin which are performed ahead of a potential decision to continue the clinical development of the drug candidate. Data generated so far from the first experiments show no difference in additional effect of arfolitixorin compared to leucovorin. Higher doses of arfolitixorin than was used in the AGENT study have been tested, but with no better effect. Further laboratory tests are ongoing and full results from the preclinical evaluation are expected to be delivered in early 2024. In previous preclinical and clinical studies, Isofol's drug candidate arfolitixorin has shown the potential to improve the efficacy of the cancer drug 5-FU, which is part of the current standard of care for colorectal cancer. However, the AGENT study, which was prematurely terminated in 2022, did not show a statistically significant difference in efficacy between arfolitixorin and the standard treatment administered in the control arm. However, an in-depth analysis of the study data indicated that a different dose and administration regimen could potentially improve the efficacy of arfolitixorin. Isofol therefore initiated a stepwise process to enable a cost-effective and risk-minimizing continued development of arfolitixorin. Isofol has now received the first results from the laboratory experiments that are part of the company's step-by-step evaluation process. Within the framework of the laboratory experiments, several tests are conducted to evaluate the effect of arfolitixorin at different doses. The tests are conducted in collaboration with external research laboratories in Norway and the United States and have gradually been extended to cell lines and organoids outside the field of colorectal cancer. The results now received have been obtained from a limited number of tests in cell lines and organoids from pancreatic tumors and cell lines from colorectal tumors. Different doses have been tested, including a higher dose of arfolitixorin than that used in the AGENT study. results of the initial experiments in pancreatic tumor cell lines and organoids show no additional effect of either arfolitixorin or leucovorin. The tests on cell lines from colorectal cancer tumors showed no additional effect. Results from laboratory experiments with colorectal cancer organoids are expected to become available in early 2024. Reported Earnings • Nov 12
Third quarter 2023 earnings released: kr0.04 loss per share (vs kr0.20 loss in 3Q 2022) Third quarter 2023 results: kr0.04 loss per share (improved from kr0.20 loss in 3Q 2022). Net loss: kr6.26m (loss narrowed 81% from 3Q 2022). Announcement • Nov 09
Isofol Medical AB (publ) Announces Appointment of Nomination Committee Members Isofol Medical AB (publ) announced that the members of the nomination committee for the Annual General Meeting 2024 have been appointed in accordance with the principles for appointing nomination committees that were adopted at the Annual General Meeting 2022. The nomination committee ahead of the AGM 2024 consists of the following members: Göran Gustafsson, representing approximately 3.31% of the shares and votes, Johan Möller, appointed by Mats Franzén representing approximately 3.29% of the shares and votes, and Lars Lind, chairman of the nomination committee, appointed by Hans Enocson representing about 2.82% of the shares and votes. In addition, representatives of minority owners representing approximately 10.83% of votes and shares have appointed Matsola Palm. The members of the nomination committee are appointed by owners who represent a total of about 20.25% of the total number of shares and votes in Isofol Medical AB (publ) according to the ownership conditions as of September 30, 2023. New Risk • Oct 10
New major risk - Revenue and earnings growth Earnings have declined by 9.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 9.4% per year over the past 5 years. Revenue is less than US$1m (kr5.5m revenue, or US$505k). Minor Risk Market cap is less than US$100m (kr133.6m market cap, or US$12.3m). Announcement • Oct 06
Isofol Medical AB (publ) Announces Results from the Modelle 001 Study Isofol Medical AB (publ) announced that the company has taken notice of the results from the investigator-initiated study Modelle 001. As previously informed, Sahlgrenska University Hospital in collaboration with Norrland University Hospital has conducted an investigator-initiated academic study, Modelle 001. The study included 30 patients and was led by Dr. Helena Taflin at Sahlgrenska University hospital in Gothenburg. The aim of the study was to examine in detail the effect of different folates (arfolitixorin/leucovorin) in combination with 5-FU on patients with colorectal cancer that has metastasized to the liver. The research team presented the final study results at the Folate Receptor Society's 8th International Symposium on Folate Biology and Therapeutics in New York on 4 October 2023. Reported Earnings • Aug 23
Second quarter 2023 earnings released: kr0.05 loss per share (vs kr0.34 loss in 2Q 2022) Second quarter 2023 results: kr0.05 loss per share (improved from kr0.34 loss in 2Q 2022). Net loss: kr7.51m (loss narrowed 86% from 2Q 2022). Revenue is expected to decline by 171% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 24%. Announcement • Jul 06
Isofol Medical AB (publ) Presents Conclusions from the In-Depth Analysis of the AGENT Study Isofol Medical AB (publ) presents the conclusions from the company's in-depth analysis of data from the Phase III study AGENT. The results from the analysis support the hypothesis that a different dose and administration regimen has the potential to improve the efficacy of the company's drug candidate arfolitixorin. Isofol has therefore decided to continue the development of arfolitixorin and is intensifying preparations for a possible start of a minor clinical study. In preclinical and clinical studies, Isofol's drug candidate arfolixorin has shown the potential to improve the efficacy the cancer drug 5-FU, which is part of the current standard treatment for colorectal cancer. However, the recent AGENT study did not show a statistically significant difference in efficacy between arfolitixorin, and the standard treatment given in the control arm. Isofol therefore initiated a stepwise process in March 2023 to enable cost-effective and risk-minimizing continued development of the drug candidate arfolitix orin. The process consists of three steps and Isofol has now completed the first step where the company has conducted an in-depth analysis of the available clinical data from the AGENT study. The aim has been to identify possible reasons why arfolitixorin in the AGENT study did not show any statistically significant difference in efficacy compared to the current standard of care. As part of the evaluation, the company, together with external experts, has also conducted PK (pharmacokinetic) modeling that calculate how drugs are absorbed, distributed and eliminated from the body. The main conclusions of the evaluation in step 1 are: The chosen dose and the administration regime of two bolus doses likely resulted in that the concentration of arfolitixor in the patients' blood was too low to deliver a sufficiently high amount of active substance into the tumor. The consequence of the low dose, in comparison with the control group with standard treatment, was not justified because the control group was treated with a higher dose. PK modeling and review of available safety data show that it is likely possible to administer arfolitixorin at a higher dose than that evaluated in the AGENT study and that a different dose and administration regimen could probably have improved the drug candidate's efficacy. Based on these conclusions, Isofol has decided to continue the development of arfolitixorin according to the previously communicated three-step process. Step two of the process has already been initiated with the Norwegian biotech company Oncosyne AS, which conducts preclinical tests in microtumors to document the effect of different doses. Results from these tests are expected after the summer. In parallel, Isofol now intends to intensify the preparations to start a minor clinical study as soon as possible, in accordance with the third and final step in the company's previously communicated strategy. However, a decision to start such a study will only be made when the results from step two are carefully analyzed. Isofol continues to protect its financial position and carefully evaluates the results of each step of the strategic plan before allocating additional resources to the project. The company estimates that the planned activities will continue to be financed from existing funds. New Risk • Jul 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr168m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (kr9.5m revenue, or US$881k). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr69m net loss next year). Market cap is less than US$100m (kr115.0m market cap, or US$10.6m). Board Change • Jul 02
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Jonas Pedersén is the most experienced director on the board, commencing their role in 2023. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Announcement • Jun 22
Isofol Medical AB (Publ) Announces Resignation of Thomas Andersson as Chief Executive Officer Isofol Medical AB (publ) announced that Thomas Andersson, at his own request, has chosen to resign as Chief Executive Officer of the company. Announcement • Jun 08
Isofol Medical AB (publ) Announces Board Changes Isofol Medical AB (publ) announced that its Board of Directors has appointed Anders Edvell as a co-opted member of the Board. This is following the resignation of Jan-Eric Österlund, who has decided to resign as Board Director and instead will take a new role as senior advisor to the company. The board has decided to co-opt Anders Edvell to the board of Isofol. Anders Edvell has over 20 years of experience in the pharmaceutical industry and is currently CEO of Immedica Pharma, a pharmaceutical company focused on commercialization of medicines for rare diseases and special diseases. He has previously been CEO at Unimedic Pharma, VP Global Product Strategies and Head of Partner Products at Sobi, Country Manager at Swedish Orphan, and held several leading medical roles at Bristol-Myers Squibb and Recip. Board Change • Jun 01
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Jonas Pedersén is the most experienced director on the board, commencing their role in 2023. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 08
First quarter 2023 earnings released: kr0.09 loss per share (vs kr0.32 loss in 1Q 2022) First quarter 2023 results: kr0.09 loss per share (improved from kr0.32 loss in 1Q 2022). Net loss: kr14.4m (loss narrowed 72% from 1Q 2022). Revenue is forecast to grow 105% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings. Announcement • May 04
Isofol Medical AB (publ) Approves Election of Annika Freij as Member of Board of Directors Isofol Medical AB (publ) at its annual general meeting held on May 3, 2023 approved the election of Annika Freij as member of the board of directors. Reported Earnings • Feb 23
Full year 2022 earnings released: kr0.99 loss per share (vs kr1.59 loss in FY 2021) Full year 2022 results: kr0.99 loss per share (improved from kr1.59 loss in FY 2021). Net loss: kr159.8m (loss narrowed 20% from FY 2021). Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Sweden. Announcement • Feb 14
Isofol Medical AB (Publ) Approves Not to Pay Extra Dividend Isofol Medical AB (publ) at its Extraordinary General Meeting held on February 13, 2023, at which proposal, regarding distribution of an extra dividend to the shareholders with SEK 0.75 per share, corresponding to a total amount of SEK 122,000,000, failed to reach the required voting majority and the resolution was therefore not adopted. Major Estimate Revision • Feb 03
Consensus EPS estimates fall by 15% The consensus outlook for fiscal year 2022 has been updated. 2022 expected loss increased from -kr1.01 to -kr1.17 per share. Revenue forecast of kr17.7m unchanged since last update. Biotechs industry in Sweden expected to see average net income growth of 65% next year. Consensus price target down from kr1.30 to kr1.14. Share price fell 6.4% to kr0.77 over the past week. Breakeven Date Change • Jan 29
No longer forecast to breakeven The 2 analysts covering Isofol Medical no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr2.90m in 2023. New consensus forecast suggests the company will make a loss of kr8.67m in 2024. Announcement • Jan 20
Isofol Medical AB (publ) Proposes Dividend, Payable on 20 February 2023 Isofol Medical AB (publ) announced that at its Extraordinary General Meeting to be held on February 13, 2022, it will propose dividend of SEK 0.7553 per share, SEK 122,000,000 in total. The record day for the distribution of dividend shall be 15 February 2023. Should the extraordinary general meeting resolve in accordance with the board of directors' proposal, distribution of dividend is expected to be effected by Euroclear Sweden AB on 20 February 2023. Breakeven Date Change • Dec 14
No longer forecast to breakeven The 2 analysts covering Isofol Medical no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr2.90m in 2023. New consensus forecast suggests the company will make a loss of kr8.67m in 2024. Major Estimate Revision • Nov 18
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from kr18.5m to kr13.0m. EPS estimate increased from -kr1.13 to -kr1.01 per share. Biotechs industry in Sweden expected to see average net income growth of 22% next year. Consensus price target of kr1.30 unchanged from last update. Share price fell 8.8% to kr0.63 over the past week. Reported Earnings • Nov 16
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2022 results: kr0.20 loss per share (improved from kr0.32 loss in 3Q 2021). Net loss: kr32.5m (loss narrowed 36% from 3Q 2021). Revenue missed analyst estimates by 17%. Earnings per share (EPS) exceeded analyst estimates by 37%. Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in Sweden. Reported Earnings • Nov 13
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2022 results: kr0.20 loss per share (improved from kr0.32 loss in 3Q 2021). Net loss: kr32.5m (loss narrowed 36% from 3Q 2021). Revenue missed analyst estimates by 17%. Earnings per share (EPS) exceeded analyst estimates by 37%. Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Sweden. Major Estimate Revision • Nov 12
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from kr18.5m to kr17.7m. 2022 losses expected to reduce from -kr1.13 to -kr1.01 per share. Biotechs industry in Sweden expected to see average net income growth of 22% next year. Consensus price target of kr1.30 unchanged from last update. Share price was steady at kr0.69 over the past week. Major Estimate Revision • Aug 30
Consensus revenue estimates fall by 40% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from kr37.2m to kr22.4m. Forecast losses increased from -kr0.86 to -kr1.13 per share. Biotechs industry in Sweden expected to see average net income growth of 8.6% next year. Consensus price target down from kr10.94 to kr1.30. Share price fell 6.6% to kr1.14 over the past week. Major Estimate Revision • Aug 17
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -kr1.23 to -kr0.86 per share. Revenue forecast unchanged from kr37.2m at last update. Biotechs industry in Sweden expected to see average net income growth of 8.6% next year. Consensus price target down from kr17.17 to kr10.94. Share price was steady at kr1.26 over the past week. Breakeven Date Change • Aug 16
Forecast breakeven date pushed back to 2024 The 3 analysts covering Isofol Medical previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 75% per year to 2023. The company is expected to make a profit of kr130.0m in 2024. Average annual earnings growth of 104% is required to achieve expected profit on schedule. Price Target Changed • Aug 05
Price target increased to kr25.00 Up from kr23.00, the current price target is an average from 3 analysts. New target price is 1,823% above last closing price of kr1.30. Stock is down 86% over the past year. The company is forecast to post a net loss per share of kr1.23 next year compared to a net loss per share of kr1.59 last year. Board Change • Jul 31
High number of new directors Chairman of the Board Jan Tornell was the last director to join the board, commencing their role in 2022. Breakeven Date Change • Jul 17
Forecast breakeven date pushed back to 2024 The 2 analysts covering Isofol Medical previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 21% per year to 2023. The company is expected to make a profit of kr250.8m in 2024. Average annual earnings growth of 91% is required to achieve expected profit on schedule. Board Change • Jun 02
High number of new directors Chairman of the Board Jan Tornell was the last director to join the board, commencing their role in 2022. Major Estimate Revision • May 19
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr37.2m to kr76.4m. EPS estimate reaffirmed at -kr1.29 per share. Biotechs industry in Sweden expected to see average net income growth of 10% next year. Consensus price target of kr23.50 unchanged from last update. Share price rose 12% to kr8.93 over the past week. Breakeven Date Change • Apr 27
Forecast to breakeven in 2023 The 4 analysts covering Isofol Medical expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr133.3m in 2023. Average annual earnings growth of 84% is required to achieve expected profit on schedule. Board Change • Apr 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Lennart Jeansson was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Mar 12
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -kr1.03 to -kr1.29 per share. Revenue forecast unchanged at kr55.7m. Biotechs industry in Sweden expected to see average net income growth of 25% next year. Consensus price target of kr23.50 unchanged from last update. Share price rose 5.0% to kr8.18 over the past week. Breakeven Date Change • Mar 10
Forecast to breakeven in 2023 The 3 analysts covering Isofol Medical expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 17% to 2022. The company is expected to make a profit of kr61.5m in 2023. Average annual earnings growth of 88% is required to achieve expected profit on schedule. Major Estimate Revision • Mar 03
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from kr100.3m to kr55.7m. EPS estimate increased from -kr1.33 to -kr1.04 per share. Biotechs industry in Sweden expected to see average net income growth of 29% next year. Consensus price target up from kr23.00 to kr23.50. Share price fell 5.2% to kr7.67 over the past week. Breakeven Date Change • Mar 02
Forecast breakeven date pushed back to 2024 The 3 analysts covering Isofol Medical previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 83% per year to 2023. The company is expected to make a profit of kr274.0m in 2024. Average annual earnings growth of 89% is required to achieve expected profit on schedule. Reported Earnings • Feb 25
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: kr1.59 loss per share (up from kr3.08 loss in FY 2020). Net loss: kr200.3m (loss widened 6.0% from FY 2020). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 26%. Over the next year, revenue is forecast to grow 348%, compared to a 205% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. Price Target Changed • Dec 06
Price target decreased to kr23.00 Down from kr25.25, the current price target is an average from 4 analysts. New target price is 147% above last closing price of kr9.32. Stock is down 47% over the past year. The company is forecast to post a net loss per share of kr1.26 next year compared to a net loss per share of kr3.07 last year. Major Estimate Revision • Dec 05
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast fell from kr22.2m to kr19.7m. EPS estimate unchanged at -kr1.26 per share. Biotechs industry in Sweden expected to see average net income growth of 4.7% next year. Consensus price target down from kr25.25 to kr23.50. Share price rose 18% to kr12.84 over the past week. Major Estimate Revision • Jul 15
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast fell from kr23.8m to kr22.7m. 2021 losses expected to reduce from -kr1.63 to -kr1.16 per share. Biotechs industry in Sweden expected to see average net income decline 7.5% next year. Consensus price target down from kr31.00 to kr25.67. Share price rose 6.9% to kr9.61 over the past week. Major Estimate Revision • May 21
Consensus revenue estimates increase to kr23.8m The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from kr19.1m to kr23.8m. Forecast losses expected to reduce from -kr2.09 to -kr1.63 per share. Biotechs industry in Sweden expected to see average net income growth of 2.4% next year. Consensus price target down from kr38.86 to kr34.67. Share price was steady at kr11.74 over the past week. Price Target Changed • May 21
Price target decreased to kr31.00 Down from kr34.75, the current price target is an average from 3 analysts. New target price is 164% above last closing price of kr11.74. Stock is up 154% over the past year. Major Estimate Revision • Mar 24
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast fell from kr25.1m to kr19.0m. EPS estimate unchanged at -kr2.09 per share. Biotechs industry in Sweden expected to see average net income growth of 1.6% next year. Consensus price target reaffirmed at kr34.75. Share price fell 36% to kr17.70 over the past week. Major Estimate Revision • Mar 05
Analysts update estimates The 2021 consensus revenue estimate increased from kr18.9m to kr25.0m. Earning per share (EPS) estimate was further reduced from -kr1.88 to -kr2.09 for the same period. The Biotechs industry in Sweden is expected to see an average net income growth of 8.7% next year. The consensus price target increased from kr33.75 to kr34.75. Share price is down by 8.3% to kr25.50 over the past week. Analyst Estimate Surprise Post Earnings • Feb 27
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 86%. Earnings per share (EPS) also surpassed analyst estimates by 14%. Over the next year, revenue is expected to shrink by 49% compared to a 146% growth forecast for the Biotechs industry in Sweden. Is New 90 Day High Low • Jan 11
New 90-day high: kr33.10 The company is up 79% from its price of kr18.50 on 13 October 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Dec 16
New 90-day high: kr19.15 The company is up 7.0% from its price of kr17.90 on 16 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 